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Introduction: The 7th American Joint Committee on Cancer (AJCC) 
tumor-node-metastasis staging system for esophageal cancer defined 
N classification based on the number of metastatic lymph nodes 
(LNs). However, this classification might neglect the extent of LNs 
metastasis. This study aimed to revise N classification based on the 
extent of LNs metastasis and propose a modification to the current 
AJCC staging system for better representing the prognostic charac-
teristics of Chinese esophageal squamous-cell carcinoma (ESCC).
Methods: We retrospectively reviewed 1993 ESCC patients who 
underwent curative resection. The proposed N categories based on 
the number of LNs metastasis stations were compared with the cur-
rent staging system by univariate and multivariate Cox regression 
analyses. Homogeneity, discriminatory ability, and monotonicity of 
gradients of two staging systems were compared using likelihood 
ratio χ2 statistics and Akaike information criterion calculations.
Results: The survival differences were not significant for N2 versus 
N3 category (p = 0.231) and stages IIIB versus IIIC (p = 0.713) based 
on the 7th AJCC staging system. When the modified staging system 
was adopted, the survival difference for N2 versus N3 and IIIB versus 
IIIC could be well discriminated. Statistical analysis showed that the 
modified staging system had higher likelihood ratio χ2 scores and 
smaller Akaike information criterion values than the 7th AJCC stag-
ing system, which represented the optimum prognostic stratification.
Conclusions: The modified staging system with the revised N cate-
gories based on the number of LNs metastasis stations better predicts 
the survival of Chinese ESCC population than the 7th AJCC staging 
system. Further studies are required to confirm this result.
Key Words: Esophageal squamous-cell carcinoma, Lymph nodes 
metastasis stations, Prognosis, 7th American Joint Committee on 
Cancer staging system.
(J Thorac Oncol. 2015;10: 1091–1098)
Cancer staging system is commonly used to unify clini-copathological classification, guide treatment deci-
sion making, evaluate prognosis, and compare treatment 
results from different institutions.1 Many studies have previ-
ously suggested that the number of metastatic lymph nodes 
(LNs) is the most important independent prognostic factor in 
esophageal cancer.2–12 The 7th version of the American Joint 
Committee on Cancer (AJCC) staging system for esopha-
geal cancer, in which Nodal (N) categories are based on the 
number of metastatic LNs, is more reliable than before.13–15 
However, this classification might have neglected the extent 
of LNs metastasis, an even more important factor in predict-
ing prognosis.16 Moreover, the exact number of metastatic 
LNs is sometimes difficult to evaluate, when an enlarged LN 
is actually the coalescence of multiple positive LNs or when 
a single enlarged LN becomes broken during surgical dissec-
tion. Moreover, it was reported by several studies that the 7th 
edition of the AJCC staging system cannot satisfactorily dis-
tinguish the prognosis among different risk groups of patients 
with resected esophageal carcinoma, especially between N2 
and N3 and between IIIB and IIIC.16,17
The current AJCC staging system for esophageal can-
cer used global data from 4627 patients.1 However, esophageal 
squamous-cell carcinoma (ESCC) patients only constitute 39.6% 
of the database (1834 of 4627) used to elaborate the 7th AJCC 
staging system for esophageal cancer.18 The most common path-
ological type of esophageal cancer in China is squamous-cell 
carcinoma type, which accounts for more than 90% of cases.19 
We believe that more data from Chinese patients are essential to 
validate the N categories in the current staging system for ESCC.
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In this retrospective study, we present data from a large 
cohorts of Chinese patients in a single institution and aimed 
to revise N staging based on the extent of LNs metastasis and 
propose a modification to the current AJCC staging system 
in order to better represent the prognostic characteristics of 
ESCC after radical esophagectomy in Chinese population.
METHODS
Patients Selection
This study was undertaken according to the Declaration 
of Helsinki at the Third Affiliated Hospital of Soochow 
University with the approval of the ethics committee at our 
institution, which waived the requirement for written informed 
consent of individual patients owing to the retrospective nature 
of this study. None of stage IV patients according to the 7th 
edition tumor-node-metastasis (TNM) system was included 
because all the patients enrolled in this study underwent radi-
cal resection and had no distant metastasis. A total of 1993 
resectable ESCC patients who underwent radical esophagec-
tomy at our institution were retrospectively reviewed from 
January 2002 to December 2011. Among 1993 patients, 672 
patients with either preoperative or postoperative radiotherapy 
and/or chemotherapy were excluded to eliminate the influence 
of adjuvant and neoadjuvant treatment. Then, 339 patients 
with less than 12 LN examined or supraclavicular LN involved 
were also excluded, as they were regarded as nonregional LN 
metastasis or insufficient LN dissection according to the sug-
gestion of AJCC.20 In the remaining 982 ESCC patients, 65 
patients were excluded because of incomplete resection and/
or perioperative death and/or lost to follow-up. Finally, 917 
patients were included into this study. Clinical data, including 
age, gender, tumor location, staging, pathology, and survival 
outcomes, were collected. Description of the LNs (number of 
involved LNs and LNs metastatic station) was also recorded.
Surgery
All patients who were conformed to be resectable ESCC 
without distant metastasis by clinical and experimental exami-
nation received radical surgical resection of a transthoracic en-
bloc esophagectomy with mediastinal and abdominal two-field 
lymphadenectomies. Mediastinal lymphadenectomies were 
performed to include subcarinal, left and right bronchial, lower 
posterior mediastinum, pulmonary ligament, and paraesopha-
geal and thoracic duct nodes. Abdominal lymphadenectomies 
were performed to include the paracardial, lesser curvature, left 
gastric, common hepatic, celiac, and splenic nodes. The para-
tracheal and recurrent laryngeal nerve LNs were also dissected. 
Cervical lymphadenectomy was only performed in case of sus-
picious cervical lymphadenopathy. Each resected node group 
was labeled by the operator.
Staging
Tumor staging was performed according to the 7th 
AJCC staging system for ESCC.20 According to Casson’s 
LN drainage map, LN metastasis station (LMS) was 
grouped and shown in Table 1.21 Four revised N categories 
(r-N: r-N0, 0 station; r-N1, 1 station; r-N2, 2 stations; r-N3, 
more than 2 stations) were classified by the number of LMS 
in this study. To compare the 7th edition AJCC TNM staging 
system, a modified TNM staging system with the revised 
N category based on the number of LMS was proposed as 
seven prognostically homogeneous classes of patients just 
as the 7th AJCC staging system (IA; IB; IIA; IIB; IIIA; 
IIIB; IIIC).
Follow-Up
All patients were followed up every 3 months for the 
first 2 years, every 6-month intervals until 5 years, and then 
annually. All patients underwent clinical, laboratory, imag-
ing, and endoscopy examination for assessing recurrence or 
metastasis. The last follow-up of survivors was conducted at 
the end of July 2014. All patients were followed up by phone 
calls and regular mail. The observation time in this study was 
the interval from the date of surgical resection to death or last 
follow-up. Surviving patients were censored on the day of the 
last contact.
Statistical Analysis
Optimal cutoff values for the number of LMS (which 
were 0, 1, and 2 station in our series) were determined using 
X-tile software (http://www.tissuearray.org/rimmlab).22 All 
statistical analyses were performed using SPSS 13.0 software 
(SPSS, Inc., Chicago, IL). Survival was calculated using the 
Kaplan–Meier method, and the log-rank test was used to 
assess differences in survival between groups. In multivariate 
analysis, forward stepwise regression analysis was carried out 
with a Cox proportional hazards model. The likelihood ratio 
χ2 test related to the Cox regression model was used for mea-
suring the homogeneity. To compare prognostic systems with 
different staging system, the Akaike information criterion 
(AIC) value was applied to measure the discriminatory abil-
ity of each prognostic model.23 AIC was defined as follows: 
AIC = –2 log maximum likelihood + 2 × (the number of 
parameters in the model). A smaller AIC value indicates a 
better model for predicting outcome. p Value less than 0.05 
from the two-sided test was considered to be statistically 
significant.
TABLE 1.  The Station and Name of Regional LN Drainage 
for Esophageal Cancer
Stationa Name Station Name
2R Right upper paratracheal nodes 9 Pulmonary ligament nodes
2L Left upper paratracheal nodes 10R Right tracheobronchial nodes
3P Posterior mediastinal nodes 10L Left tracheobronchial nodes
4R Right lower paratracheal nodes 15 Diaphragmatic nodes
4L Left lower paratracheal nodes 16 Paracardial nodes
5 Aortopulmonary nodes 17 Left gastric nodes
6 Anterior mediastinal nodes 18 Common hepatic nodes
7 Subcarinal nodes 19 Splenic nodes
8M Middle paraesophageal LNs 20 Celiac node
aSupraclavicular lymph node was not included because of being regarded as 
nonregional LN metastasis.
LN, lymph node.
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RESULTS
Patients and Clinicopathological Characteristics
Among the 917 patients enrolled in this study, 690 
(75.2%) were male patients, and 227 (24.8%) were female 
patients. The median age of the patients at surgery was 60 
years (range, 37–85 yr). Four hundred thirty-four patients 
(47.3%) had LN metastasis. Most tumors originated from the 
mid esophagus (65.6%). The overall 5-year survival rate for 
all patients was 44.5%, and 406 patients were alive when the 
follow-up was completed. Detailed patients characteristics 
and pathologic variables are summarized in Table 2.
Survival Analyses
In univariate analysis, age, gender, tumor differentia-
tion, pT category, pN category, and r-pN (based on the num-
ber of LMS) category were found to be significant prognostic 
factors (Table 2). In our study, the pN and r-pN classifications 
were highly correlated. Therefore, two separate multivariate 
models, one with pN and the other with r-pN, were run to 
avoid problems with the presence of multicollinearity. In mul-
tivariate analysis, pT category, pN category, and r-pN were 
independent prognostic factors (Table 3).
The 5-year survival rates according to the different pN 
and r-pN categories were shown in Figure 1. The Kaplan–
Meier plots showed a good discriminatory ability in both pN 
and r-pN categories, except for pN2 versus pN3 in N category 
(p = 0.231) (Fig. 1A and B). The 5-year survival rates of pN0, 
pN1, pN2, and pN3 patients were 61.0%, 31.6%, 17.3%, and 
9.5%, respectively (p < 0.001). The 5-year survival rates of 
r-pN0, r-pN1, r-pN2, and r-pN3 patients were 61.0%, 33.5%, 
21.9%, and 8.3%, respectively (p < 0.001). Pair comparison 
of adjacent subgroups for LN status showed improvement 
in separation of r-pN2 versus r-pN3 by the revised staging 
(p < 0.001), compared with LN status by the current 7th 
N-staging classification.
By analyzing all the seven substages in the 7th AJCC 
staging system, there are significant survival differences 
among seven groups (p < 0.001; Fig. 1C). However, we found 
that stages IIIB and IIIC had similar survival curves between 
(p = 0.713; Fig. 1C). In the subsequent analysis, we modi-
fied the current staging system using our redefined N category 
without any other alteration to the 7th AJCC staging system. 
Overall survival among seven subgroups is significantly dif-
ferent (p < 0.001), and the survival curves between stages IIIB 
and IIIC in the modified AJCC staging system could be easily 
distinguished (p = 0.011; Fig. 1D).
To evaluate the utility of the N categories for predicting 
survival in different pathologic T categories, we performed 
stratified analysis in the T2 and T3 subgroups based on the 7th 
AJCC TNM staging system in the entire cohort of patients. 
We only included the cases with T2 and T3 disease for sub-
group analysis because the number of Tis-T1 (n = 43) and T4 
(n = 12) subgroups with LNs involved was too small to be 
further studied in stratified analysis. In the T2 subgroup, there 
were no differences in survival between patients with patho-
logical N2 and N3 stages (p = 0.301; Fig. 2A). A similar result 
was also observed in the T3 subgroup (p = 0.477; Fig. 2B).
To evaluate the utility of the revised N categories in pre-
dicting survival, similar subgroups analyses were conducted 
based on the modified AJCC staging system with the revised 
TABLE 2.  Patient Demographics and Results of Univariate 
Analysis for Overall Survival (n = 917)
n (%)
Median  
Survival (mo)
5-Yr  
Survival (%) p
Age, yr 0.029
  ≤60 462 (50.4%) 50 46.7
  >60 455 (49.6%) 34 42.4
gender 0.027
  Male 690 (75.2%) 39.2 42.6
  Female 227 (24.8%) 70 50.4
Location 0.750
  Proximal esophagus 59 (6.4%) 34 48.9
  Mid esophagus 601 (65.6%) 40 43.1
  Distal esophagus 257 (28%) 50 46.8
Differentiation <0.001
  Well 48 (5.2%) Not reached 80.5
  Moderately 451 (49.2%) 58.4 49.9
  Poorly 418 (45.6%) 29 34.7
T stage <0.001
  Tis-T1 210 (22.9%) Not reached 73.1
  T2 235 (25.6%) 82.7 52.3
  T3 460 (50.2%) 25 28.5
  T4 12 (1.3%) 13 16.7
N stage <0.001
  pN0 483 (52.7%) 110 61.0
  pN1 270 (29.4%) 29 31.6
  pN2 122 (13.3%) 17 17.3
  pN3 42 (4.6%) 13 9.5
Revised N stage <0.001
  r-pN0 483 (52.7%) 110 61.0
  r-pN1 236 (25.7%) 32 33.5
  r-pN2 107 (11.7%) 22 21.9
  r-pN3 91 (9.9%) 13 8.3
7th AJCC staging <0.001
  0 + IA 40 (4.4%) Not reached 92.4
  IB 130 (14.2%) Not reached 76.1
  IIA 82 (8.9%) 75 55.4
  IIB 330 (36%) 52 47.4
  IIIA 191 (20.8%) 24 26.3
  IIIB 92 (10%) 16 13.9
  IIIC 52 (5.7%) 14 11.2
Modified staging <0.001
  0 + IA 40 (4.4%) Not reached 92.4
  IB 130 (14.2%) Not reached 76.1
  IIA 82 (8.9%) 75 55.4
  IIB 319 (34.8%) 55 48.4
  IIIA 171 (18.6%) 26 27.7
  IIIB 75 (8.2%) 21 18.9
  IIIC 100 (10.9%) 13 8.3
AJCC, American Joint Committee on Cancer.
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N categories. In the T2 subgroup, survival could be distin-
guished between patients with r-pN2 and r-pN3 in the entire 
cohort of patients (p = 0.04; Fig. 3A). The survival between 
patients with r-pN2 and r-pN3 stages can also be distinguished 
in the T3 subgroup (p = 0.018; Fig. 3B).
The proportion of patients who migrated between 
stages when the modified AJCC staging system was applied 
was summarized in Table 4. There were no changes observed 
in ESCC stage 0-IA, IB, and IIA, but significant changes 
were observed in ESCC stage IIB and III. From the 7th AJCC 
staging system to the modified AJCC staging system, 31.3% 
of the patients with LNs metastasis (136 of 434) in the entire 
cohort change their AJCC stage, with major changes includ-
ing IIIA migrating to IIIB and IIIB migrating to IIIC.
The performance between the 7th AJCC and the modi-
fied staging systems, as well as between the 7th N staging and 
the revised N staging defined according to the number of LMS, 
was assessed by likelihood ratio χ2 and the AIC tests (Table 5). 
Compared with the 7th AJCC staging system, the modified 
staging system had better homogeneity (higher likelihood ratio 
χ2 score, 248.5 versus 225). Furthermore, in our study, the 
modified staging system had a smaller AIC value (6307.3 ver-
sus 6322.4), representing an optimum prognostic stratification.
DISCUSSION
The reasonable staging system should abide by the fol-
lowing basic principles. First, subgroups with the different 
T, N, and M combinations in the same stage should have the 
similar survival (the uniform of risk). Second, there should 
be a different survival rate between each stage (the difference 
of risk). Third, there is higher predictive value for survival 
according to the staging system (the predictability of survival).
LN metastasis is the most important independent prog-
nostic factor affecting long-term survival in patients with 
esophageal cancer after curative resection. Some studies, 
which attempted to validate the 7th nodal staging, reported 
that this nodal classification enabled risk stratification for over-
all survival after surgery and was an independent predictor 
of survival in esophageal cancer.14,17 Despite the current 7th 
AJCC staging for esophageal cancer provides a great improve-
ment over previous editions with the N category by stratifying 
patients based on the different numbers of LNs involved, sev-
eral studies have found no significant differences in prognosis 
between pN2 and pN3 patients. Chen et al.24 retrospectively 
reviewed 2011 Chinese ESCC patients who underwent surgical 
resection alone and reported that the survival differences were 
not significant between pN2 and pN3 categories. Yamasaki 
et al.15 also investigated the significance of 7th edition of the 
Union for International Cancer Control-TNM staging system 
on differentiating the survival of 665 ESCC patients after 
esophagectomy and found that there were no significant differ-
ences in survival between patients with pN2 and pN3. Another 
study by Xu et al.16 reported that the N category based on the 
7th AJCC staging system was not satisfactory because of simi-
lar prognosis in ESCC between patients with pN2 and pN3.
Moreover, Hsu et al.13 and other investigators have dem-
onstrated that not only pN2 versus pN3 but also stage IIIB 
versus IIIC showed no significant difference in the survival of 
patients with ESCC.25 In this study, we also showed that no sig-
nificant differences was observed in the survival between pN2 
and pN3 patients according to 7th edition AJCC staging sys-
tem (p = 0.231). Similar result was also found in the survival 
between IIIB and IIIC patients according to 7th AJCC staging 
system (p = 0.713). All of these data were assembled from 
Asian patients with ESCC. The reasons for the difference in 
survival between ESCC patients from Asia and predominantly 
adenocarcinoma patients from the Worldwide Esophageal 
Cancer Collaboration need to be further investigated.
TABLE 3.  Cox Multivariate Regression Analyses for the 
Influence of Clinicopathological Characteristics on Overall 
Survival in Patients with ESCC (n = 917)
Variables
Hazard 
Ratio p 95% CI
Multivariate model with 7th AJCC
  Age 1.273 0.007 1.067–1.517
  gender 1.126 0.283 0.906–1.400
  Location (baseline, proximal  
 esophagus)
0.376
   Mid esophagus 0.825 0.307 0.570–1.194
   Distal esophagus 0.761 0.173 0.513–1.127
  Differentiation (baseline, well) 0.004
   Moderately 1.918 0.060 0.973–3.780
   Poorly 2.411 0.011 1.222–4.758
  7th AJCC T (baseline, Tis-T1) <0.001
   T2 1.613 0.003 1.171–2.221
   T3 2.564 <0.001 1.920–3.424
   T4 3.722 <0.001 1.872–7.401
  7th AJCC N (baseline, N0) <0.001
   pN1 1.656 <0.001 1.338–2.050
   pN2 2.678 <0.001 2.070–3.465
   pN3 3.832 <0.001 2.673–5.494
Multivariate model with modified  
 staging system
  Age 1.269 0.008 1.065–1.511
  gender 1.113 0.336 0.895–1.384
  Location (baseline, proximal  
 esophagus)
0.461
   Mid esophagus 0.818 0.284 0.565–1.182
   Distal esophagus 0.779 0.214 0.526–1.154
  Differentiation (baseline, well) 0.005
   Moderately 1.923 0.059 0.975–3.794
   Poorly 2.388 0.012 1.209–4.716
  7th AJCC T (baseline, T1) <0.001
   T2 1.572 0.006 1.141–2.168
   T3 2.476 <0.001 1.850–3.315
   T4 3.908 <0.001 1.964–7.777
  Revised N (baseline, N0) <0.001
   r-pN1 1.606 <0.001 1.286–2.005
   r-pN2 2.235 <0.001 1.702–2.936
   r-pN3 3.604 <0.001 2.734–4.749
ESCC, esophageal squamous-cell carcinoma; CI, confidence interval; AJCC, 
American Joint Committee on Cancer.
Copyright © 2015 by the International Association for the Study of Lung Cancer
1095Copyright © 2015 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 10, Number 7, July 2015 Proposed Modification of Nodal Staging
N category according to the 7th edition of AJCC staging 
system only considers the number of LN metastasis and does 
not take into account the extent of LN metastasis. Logically, 
given the same number of involved LNs, the prognosis might 
differ between the patients with metastatic LNs clustered in 
one anatomic LN station and those with metastatic LNs dis-
tributed to more than two LN stations. Therefore, this study 
was carried out to evaluate the performance of new N category 
and the modified AJCC staging system based on the number 
of LMS. The revised N category covered both extent-depen-
dent staging and numerically based classification. To the best 
of our knowledge, this is the first study to assess the prognos-
tic difference value of the number of LMS in ESCC patients 
by making comparisons with 7th N staging. Furthermore, our 
results demonstrated that N category based on the number of 
LMS was an independent prognostic predictor for long-term 
survival in Chinese patients with ESCC and could make better 
stratification for the ESCC patients with different prognosis 
compared with the 7th nodal staging. Because the patho-
logic T category is a well-established independent prognostic 
factor, we evaluated the survival differences between groups 
with different nodal stage for different T classification. 
Significant differences in survival were observed in pT2 and 
pT3 subgroups between patients with the different revised N 
categories, whereas with the N categories based on the 7th 
AJCC staging system, no significant difference between N2 
and N3 was found in pT2 and pT3 subgroups. With the revised 
N categories applied to modify the existing AJCC staging 
system, we found that survival curves stratified according to 
the modified staging system did not overlap, which is in con-
trast to the curves of the 7th AJCC staging system (i.e., stage 
IIIB and IIIC). Furthermore, comparison of the current nodal 
FIGURE 1.  Kaplan–Meier survival curves for patients stratified by according to the 7th American Joint Committee on Cancer 
(AJCC) nodal categories (A), revised N categories based on the number of lymph node metastasis station (B), the 7th AJCC-TNM 
staging system (C), and modified staging system with the revised N categories based on the number of lymph node metastasis 
station (D). TNM, tumor-node-metastasis.
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staging to the proposed staging system revealed that the modi-
fied staging system has better performance than the 7th AJCC 
staging system in terms of homogeneity, discriminatory, and 
prognostic stratification because of higher likelihood ratio χ2 
and lower AIC in Cox regression models.
Previous studies have redefined N categories based on the 
number of LNs metastasis fields (LMF) and evaluated the sig-
nificance of LMF number on the prognosis of esophageal can-
cer.16,26,27 In these studies, LMF were defined as neck, chest, and 
abdomen field. Both these studies showed that further stratifica-
tion according to the number of LMF can effectively discrimi-
nate between LN-positive patients. However, the performance of 
the modified staging systems based on the revised N categories 
was not evaluated, which may be due to the inhomogeneity of 
gradients in patients stratified by the number of LMF (i.e., few 
patients grouped to the three field). Despite the abovementioned 
limitation, the results in these studies hinted to us that the extent 
of LN metastasis, rather than the number alone, might be a bet-
ter nodal staging method. In this study, we demonstrated that the 
modified staging system with the revised N categories based on 
the number of LMS stratified the prognosis of ESCC patients 
more accurately than the 7th AJCC staging system.
Despite of the advantages of revised N stage applied in the 
prediction of survival, we recognize that there are some limita-
tions in this study that have to be considered in the interpreta-
tion of these results. First, the relatively small patient numbers 
FIGURE 2. A, Survival curves for T2 patients stratified by the 7th American Joint Committee on Cancer (AJCC) nodal catego-
ries (n = 235; among four categories, p < 0.001; pN2 versus pN3, p = 0.301). B, Survival curves for T3 patients stratified by 7th 
AJCC nodal categories (n = 460; among four categories, p < 0.001; pN2 versus pN3, p = 0.477).
FIGURE 3. A, Survival curves for T2 patients stratified by the revised nodal categories based on the number of lymph node 
metastasis station (n = 235; among four categories, p < 0.001; r-pN2 versus r-pN3, p = 0.04). B, Survival curves for T3 patients 
stratified by the revised nodal categories (n = 460; among four categories, p < 0.001; r-pN2 versus r-pN3, p = 0.018).
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in some subgroups, especially in the T2 subgroup, may limit 
statistical power. Second limitation is the retrospective nature of 
this study. A multicenter collaborative study with a large cohort 
would be required to substantiate the result. However, it is worth 
to mention that the patients enrolled in this study from single 
institution underwent highly uniform surgical procedures, path-
ological examination, and follow-up throughout the whole study 
period. Third, most of patients in this underwent mediastinal and 
abdominal two-field lymphadenectomy without cervical lymph-
adenectomy. Three-field lymphadenectomy could provide more 
accurate pathologic N stage. However, several studies evaluated 
the prognostic role of three-field lymphadenectomy for ESCC 
patients and suggested that the addition of cervical nodal dissec-
tion did not provide a survival benefit.28–30 Moreover, extensive 
lymphadenectomy is not free of additional risks of complica-
tions and may reduce postoperative recover and quality of 
life.31,32 Therefore, more extensive lymphadenectomy should be 
balanced against the risk of postoperative complications. Finally, 
as this study is focused on ESCC, our proposed modification for 
AJCC staging system cannot be directly applied in esophageal 
adenocarcinoma. In the future, the staging system needs to be 
classified separately according to the histopathological cell type, 
for example, ESCC and esophageal adenocarcinoma.
CONCLUSIONS
In conclusion, we suggest that N categories of ESCC 
based on the number of LMS, considering both the number 
and the extent of LNs metastasis, could provide a better basis 
for distinguishing subgroups of patients with different prog-
nosis after radical esophagectomy compared with 7th nodal 
staging based on the number of metastatic LNs alone. Further 
validation on a multicenter, large data set is warranted, espe-
cially when defining the next edition of the AJCC staging sys-
tem for esophageal cancer.
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